OLA
JAZZ icon

Oliver Luxxe Assets’s Jazz Pharmaceuticals JAZZ Stock Holding History

Oliver Luxxe Assets’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.54M Sell
18,860
-190
-1% -$41.6K 0.67% 57
2026
Q1 		$3.6M Buy
+19,050
New +$3.33M 0.54% 66
2022
Q3 		– Sell
-11,649
Closed -$1.82M – 186
2022
Q2 		$1.82M Buy
+11,649
New +$1.79M 0.54% 68

Other funds holding JAZZ

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BCM
BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Oliver Luxxe Assets's JAZZ Position: Q2 2026 in Review

Oliver Luxxe Assets reduced its Jazz Pharmaceuticals (JAZZ) stake by 1% in Q2 2026, selling an estimated $41.6K and leaving 18,860 shares worth $4.54M. The position accounts for 0.67% of the portfolio, ranked #57.

Oliver Luxxe Assets first reported a position in JAZZ in Q2 2022 and has held it in 3 quarters since. 69 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Oliver Luxxe Assets held 18,860 shares of Jazz Pharmaceuticals worth $4.54M as of Q2 2026.
  • Oliver Luxxe Assets sold 190 Jazz Pharmaceuticals shares in Q2 2026, an estimated $41.6K.
  • Jazz Pharmaceuticals made up 0.67% of Oliver Luxxe Assets's portfolio in Q2 2026, its #57 holding.
  • Oliver Luxxe Assets first reported a position in Jazz Pharmaceuticals in Q2 2022 and has held it in 3 quarters since.
  • 69 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Oliver Luxxe Assets's 13F filing for Q2 2026, filed 9 Jul 2026.